Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
ALLEN, Texas, May 10, 2017 -- Atrion Corporation (Nasdaq:ATRI) today announced diluted earnings per share for the first quarter of 2017 were $5.36 as compared to $3.74 in the first quarter of 2016. Revenues for the quarter ended March 31, 2017 were $38.5 million compared with $36.2 million in the same period in 2016. Net income in the current-year quarter totaled $10.0 million compared to $6.9 million in last year’s first quarter.
Commenting on the Company’s results for the first quarter of 2017 compared to the same period last year, David A. Battat, President & CEO, said, “Sales were up 6%, with Ophthalmology and Fluid Delivery showing growth and aided by relatively stable foreign exchange rates. With improved scale in manufacturing, operating income increased by 8%." Mr. Battat added, “Diluted earnings per share were up 43% from last year's $3.74, reflecting, in part, a tax benefit related to employee stock compensation that lowered our tax rate to 13% compared to 32% in the first quarter of 2016. Excluding the tax benefit, diluted EPS for the quarter increased 11%, generally in line with the increase in our operating income.” Mr. Battat concluded, “Cash and short and long term investments increased by $2.0 million to a total of $56.0 million as of March 31, 2017.”
Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.
| ATRION CORPORATION CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share data) (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2017 | 2016 | |||||||
| Revenues | $ | 38,504 | $ | 36,215 | ||||
| Cost of goods sold | 19,873 | 18,650 | ||||||
| Gross profit | 18,631 | 17,565 | ||||||
| Operating expenses | 7,304 | 7,100 | ||||||
| Operating income | 11,327 | 10,465 | ||||||
| Interest income | 149 | 123 | ||||||
| Other income (expense), net | -- | (345 | ) | |||||
| Income before income taxes | 11,476 | 10,243 | ||||||
| Income tax provision | (1,526 | ) | (3,298 | ) | ||||
| Net income | 9,950 | 6,945 | ||||||
| Income per basic share | $ | 5.42 | $ | 3.81 | ||||
| Weighted average basic shares outstanding | 1,835 | 1,823 | ||||||
| Income per diluted share | $ | 5.36 | $ | 3.74 | ||||
| Weighted average diluted shares outstanding | 1,855 | 1,857 | ||||||
| ATRION CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands) | |||||
| Mar. 31, | Dec. 31, | ||||
| ASSETS | 2017 | 2016 | |||
| (Unaudited) | |||||
| Current assets: | |||||
| Cash and cash equivalents | $ | 17,529 | $ | 20,022 | |
| Short-term investments | 29,019 | 24,080 | |||
| Total cash and short-term investments | 46,548 | 44,102 | |||
| Accounts receivable | 20,679 | 17,166 | |||
| Inventories | 30,354 | 29,015 | |||
| Prepaid expenses and other | 2,003 | 3,181 | |||
| Total current assets | 99,584 | 93,464 | |||
| Long-term investments | 9,463 | 9,945 | |||
| Property, plant and equipment, net | 65,601 | 65,265 | |||
| Other assets | 13,141 | 13,268 | |||
| $ | 187,789 | $ | 181,942 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||
| Current liabilities | 10,124 | 9,073 | |||
| Line of credit | -- | -- | |||
| Other non-current liabilities | 9,969 | 9,881 | |||
| Stockholders’ equity | 167,696 | 162,988 | |||
| $ | 187,789 | $ | 181,942 | ||
NON-GAAP FINANCIAL MEASURE RECONCILIATION
(In thousands, except per share data)
Included in our news release is a non-GAAP financial measure that is calculated by excluding certain tax benefits that are included in financial measures determined in accordance with GAAP. We have provided this non-GAAP measure as an additional tool for investors to better understand our operating results and to facilitate a comparison of the periods shown. This measure should be considered in addition to, rather than as a substitute for, GAAP measures of the Company's performance. The table below provides a reconciliation of this non-GAAP financial measure with the most directly comparable GAAP financial measure.
| Three Months Ended March 31, | % | ||||||||||||
| 2017 | 2016 | Increase | |||||||||||
| GAAP net income | $ | 9,950 | $ | 6,945 | |||||||||
| Minus tax benefit related to employee stock compensation | 2,270 | -- | |||||||||||
| Adjusted net income (non-GAAP) | $ | 7,680 | $ | 6,945 | |||||||||
| Weighted average diluted shares outstanding | 1,855 | 1,857 | |||||||||||
| Adjusted income per diluted share (non-GAAP) | $ | 4.14 | $ | 3.74 | 11 | % | |||||||
| GAAP income per diluted share | $ | 5.36 | $ | 3.74 | 43 | % | |||||||
Jeffery Strickland Vice President and Chief Financial Officer (972) 390-9800
